Company intelligence / Profile preview

Bioven

Kuala Lumpur, Malaysiabioveningredients.com ↗

Ownership: Private
Development stage: Commercial

Overview

Bioven has two distinct entities in the search results: 1) Bioven, a late-stage biopharmaceutical company developing EGF-PTI (CIMAvax-EGF), a novel immunotherapy for non-small cell lung cancer currently in Phase III trials[2][6]; 2) Bioven by Biopharma Plasma, currently in Phase III for COVID-19 Pneumonia with an 8% phase transition success rate for progressing into Pre-Registration[4]. There's also Bioven Ingredients, which manufactures enzymes, probiotics, and micronutrient premixes[1].

Therapeutic areas: OncologyPulmonologyInfectious DiseasesHematology
Modalities: ImmunotherapyPlasma-derived medicines
Industry: Biotech

Partnerships

CIMAB SA (Cuba)Centre of Molecular Immunology (CIM) in CubaCancer Beatson Institute in Glasgow

Beyond the preview

Go deeper on Bioven.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bioven.

Explore the full profile